ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

ClinicalTrials.gov ID: NCT02436759

Public ClinicalTrials.gov record NCT02436759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Study identification

NCT ID
NCT02436759
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Enrollment
140 participants

Conditions and interventions

Interventions

  • RVL-1201 Drug
  • RVL-1201 Vehicle Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2015
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016
Last update posted
Oct 27, 2021

2015 – 2016

United States locations

U.S. sites
14
U.S. states
7
U.S. cities
14
Facility City State ZIP Site status
Not listed Artesia California 90701
Not listed Newport Beach California 92663
Not listed Rancho Cordova California 95670
Not listed Santa Maria California 93454
Not listed Fort Myers Florida 33901
Not listed Largo Florida 33773
Not listed Plantation Florida 33324
Not listed Sarasota Florida 34239
Not listed Roswell Georgia 30076
Not listed Pittsburg Kansas 66762
Not listed Shawnee Mission Kansas 66204
Not listed Mason Ohio 45040
Not listed Kingston Pennsylvania 18704
Not listed Nashville Tennessee 37215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02436759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 27, 2021 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02436759 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →